FDA Approves Roche's Gazyva for Lupus Nephritis Treatment, Expanding Therapeutic Options
Key Insights
The FDA has approved Roche's lymphoma (search) drug Gazyva to treat lupus nephritis (search), a kidney-related complication of systemic lupus erythematosus (search).
The approval was based on a Phase 3 trial showing 46% of patients achieved renal response with Gazyva combination therapy compared to 33% with placebo.
Gazyva will be used alongside steroids and other immunosuppressants, providing patients with an additional treatment option for controlling lupus nephritis (search).
The Food and Drug Administration has approved Roche's lymphoma (search) drug Gazyva (obinutuzumab) to treat lupus nephritis (search), a kidney-related complication of systemic lupus erythematosus (search), the company announced Sunday. This approval represents a significant expansion of treatment options for patients with this serious autoimmune condition.
Clinical Trial Results Drive Approval
Gazyva won approval based on results from a Phase 3 trial that evaluated the drug as an add-on to standard therapy. The study compared a triple combination of Gazyva with CellCept (mycophenolate mofetil) and prednisone against standard therapy with a placebo.
The results demonstrated clinically meaningful improvement in renal response rates. In the Gazyva group, 46% of patients achieved renal response, defined by a reduction in the amount of protein in the urine, compared with 33% in the placebo group receiving standard therapy alone.
Expanding Treatment Arsenal
The approval will give patients another treatment option to use alongside steroids and other immunosuppressants to control lupus nephritis (search). This represents an important addition to the therapeutic landscape for managing this challenging kidney complication of systemic lupus erythematosus (search).
Gazyva, originally developed and approved for certain types of lymphoma (search), is a CD20 (search)-directed cytolytic antibody that works by targeting B cells, which play a key role in the autoimmune processes underlying lupus nephritis (search).
Clinical Significance
Lupus nephritis (search) affects a significant portion of patients with systemic lupus erythematosus (search) and can lead to serious kidney damage if not properly managed. The availability of additional therapeutic options like Gazyva provides clinicians with more tools to help patients achieve better disease control and potentially preserve kidney function.